Is AGEN or MYGN more profitable?

Agenus has a net margin of 50.49% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% Myriad Genetics -48.24% -8.51% -4.48%

Does the media refer more to AGEN or MYGN?

In the previous week, Agenus had 21 more articles in the media than Myriad Genetics. MarketBeat recorded 24 mentions for Agenus and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.08 beat Agenus' score of 0.18 indicating that Myriad Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 4 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, XOMA or AGEN?

XOMA Royalty has higher earnings, but lower revenue than Agenus. Agenus is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XOMA Royalty $52.15M 9.66 $31.71M $1.57 25.59 Agenus $114.20M 2.24 $120K $1.59 3.87

Is XOMA or AGEN more profitable?

XOMA Royalty has a net margin of 53.46% compared to Agenus' net margin of 50.49%. XOMA Royalty's return on equity of 12.56% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets XOMA Royalty 53.46% 12.56% 4.11% Agenus 50.49% -31.66% 42.71%

Does the media favor XOMA or AGEN?

In the previous week, Agenus had 20 more articles in the media than XOMA Royalty. MarketBeat recorded 24 mentions for Agenus and 4 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 1.54 beat Agenus' score of 0.18 indicating that XOMA Royalty is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA Royalty 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Agenus 4 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, AGEN or CBIO?

Agenus has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 2.24 $120K $1.59 3.87 Crescent Biopharma $10.84M 39.89 -$153.94M -$10.91 N/A

Is AGEN or CBIO more profitable?

Agenus has a net margin of 50.49% compared to Crescent Biopharma's net margin of 0.00%. Agenus' return on equity of -31.66% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% Crescent Biopharma N/A -103.44% -88.19%

Which has stronger earnings and valuation, VSTM or AGEN?

Agenus has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 15.27 -$209.47M -$2.70 N/A Agenus $114.20M 2.24 $120K $1.59 3.87

Is VSTM or AGEN more profitable?

Agenus has a net margin of 50.49% compared to Verastem's net margin of -391.17%. Agenus' return on equity of -31.66% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -391.17% -486.40% -91.56% Agenus 50.49% -31.66% 42.71%

Does the media favor VSTM or AGEN?

In the previous week, Agenus had 20 more articles in the media than Verastem. MarketBeat recorded 24 mentions for Agenus and 4 mentions for Verastem. Verastem's average media sentiment score of 0.89 beat Agenus' score of 0.18 indicating that Verastem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 4 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral

Agenus (AGEN) Competitors

$6.22 +0.10 (+1.63%)

As of 09:59 AM Eastern

Compare

AGEN vs. MYGN, XOMA, CBIO, EBS, and VSTM

Should you buy Agenus stock or one of its competitors? MarketBeat compares Agenus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Agenus include Myriad Genetics (MYGN), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), Emergent Biosolutions (EBS), and Verastem (VSTM). These companies are all part of the "biotechnology" industry.

How does Agenus compare to Myriad Genetics?

Agenus (NASDAQ:AGEN) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Agenus has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	2.24	$120K	$1.59	3.87
Myriad Genetics	$824.50M	0.67	-$365.90M	-$4.30	N/A

61.5% of Agenus shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 6.5% of Agenus shares are owned by insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Agenus has a net margin of 50.49% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Myriad Genetics	-48.24%	-8.51%	-4.48%

Agenus has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

In the previous week, Agenus had 21 more articles in the media than Myriad Genetics. MarketBeat recorded 24 mentions for Agenus and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.08 beat Agenus' score of 0.18 indicating that Myriad Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	4 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agenus currently has a consensus price target of $30.00, indicating a potential upside of 387.80%. Myriad Genetics has a consensus price target of $6.50, indicating a potential upside of 10.92%. Given Agenus' higher probable upside, equities analysts clearly believe Agenus is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Agenus beats Myriad Genetics on 9 of the 14 factors compared between the two stocks.

How does Agenus compare to XOMA Royalty?

XOMA Royalty (NASDAQ:XOMA) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

XOMA Royalty has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Agenus has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

XOMA Royalty has higher earnings, but lower revenue than Agenus. Agenus is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15M	9.66	$31.71M	$1.57	25.59
Agenus	$114.20M	2.24	$120K	$1.59	3.87

In the previous week, Agenus had 20 more articles in the media than XOMA Royalty. MarketBeat recorded 24 mentions for Agenus and 4 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 1.54 beat Agenus' score of 0.18 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Agenus	4 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral

XOMA Royalty has a net margin of 53.46% compared to Agenus' net margin of 50.49%. XOMA Royalty's return on equity of 12.56% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	53.46%	12.56%	4.11%
Agenus	50.49%	-31.66%	42.71%

95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 8.9% of XOMA Royalty shares are held by insiders. Comparatively, 6.5% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

XOMA Royalty currently has a consensus target price of $53.75, suggesting a potential upside of 33.81%. Agenus has a consensus target price of $30.00, suggesting a potential upside of 387.80%. Given Agenus' higher probable upside, analysts plainly believe Agenus is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

XOMA Royalty beats Agenus on 9 of the 15 factors compared between the two stocks.

How does Agenus compare to Crescent Biopharma?

Agenus (NASDAQ:AGEN) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Agenus currently has a consensus price target of $30.00, indicating a potential upside of 387.80%. Crescent Biopharma has a consensus price target of $29.40, indicating a potential upside of 87.38%. Given Agenus' higher possible upside, equities analysts clearly believe Agenus is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Agenus has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	2.24	$120K	$1.59	3.87
Crescent Biopharma	$10.84M	39.89	-$153.94M	-$10.91	N/A

Agenus has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

61.5% of Agenus shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 6.5% of Agenus shares are owned by company insiders. Comparatively, 8.7% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Agenus had 23 more articles in the media than Crescent Biopharma. MarketBeat recorded 24 mentions for Agenus and 1 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 1.89 beat Agenus' score of 0.18 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Agenus	Neutral
Crescent Biopharma	Very Positive

Agenus has a net margin of 50.49% compared to Crescent Biopharma's net margin of 0.00%. Agenus' return on equity of -31.66% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Crescent Biopharma	N/A	-103.44%	-88.19%

Summary

Agenus beats Crescent Biopharma on 10 of the 17 factors compared between the two stocks.

How does Agenus compare to Emergent Biosolutions?

Emergent Biosolutions (NYSE:EBS) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Emergent Biosolutions has higher revenue and earnings than Agenus. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.56	$52.60M	-$0.28	N/A
Agenus	$114.20M	2.24	$120K	$1.59	3.87

Emergent Biosolutions currently has a consensus target price of $12.00, indicating a potential upside of 49.68%. Agenus has a consensus target price of $30.00, indicating a potential upside of 387.80%. Given Agenus' higher possible upside, analysts clearly believe Agenus is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Agenus had 24 more articles in the media than Emergent Biosolutions. MarketBeat recorded 24 mentions for Agenus and 0 mentions for Emergent Biosolutions. Agenus' average media sentiment score of 0.18 beat Emergent Biosolutions' score of 0.00 indicating that Agenus is being referred to more favorably in the news media.

Company	Overall Sentiment
Emergent Biosolutions	Neutral
Agenus	Neutral

Emergent Biosolutions has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market. Comparatively, Agenus has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Agenus has a net margin of 50.49% compared to Emergent Biosolutions' net margin of -1.27%. Emergent Biosolutions' return on equity of 10.76% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-1.27%	10.76%	4.22%
Agenus	50.49%	-31.66%	42.71%

78.4% of Emergent Biosolutions shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by insiders. Comparatively, 6.5% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Agenus beats Emergent Biosolutions on 9 of the 16 factors compared between the two stocks.

How does Agenus compare to Verastem?

Verastem (NASDAQ:VSTM) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Agenus has a net margin of 50.49% compared to Verastem's net margin of -391.17%. Agenus' return on equity of -31.66% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
Agenus	50.49%	-31.66%	42.71%

Verastem has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Agenus has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

88.4% of Verastem shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 6.5% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Verastem presently has a consensus target price of $14.40, indicating a potential upside of 168.16%. Agenus has a consensus target price of $30.00, indicating a potential upside of 387.80%. Given Agenus' higher probable upside, analysts plainly believe Agenus is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Agenus has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	15.27	-$209.47M	-$2.70	N/A
Agenus	$114.20M	2.24	$120K	$1.59	3.87

In the previous week, Agenus had 20 more articles in the media than Verastem. MarketBeat recorded 24 mentions for Agenus and 4 mentions for Verastem. Verastem's average media sentiment score of 0.89 beat Agenus' score of 0.18 indicating that Verastem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	4 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral

Summary

Agenus beats Verastem on 11 of the 17 factors compared between the two stocks.

Get Agenus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGEN vs. The Competition

Export

Metric	Agenus	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$139.50M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	3.87	20.85	27.10	24.26
Price / Sales	2.24	314.01	588.85	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	-0.75	8.49	10.85	6.29
Net Income	$120K	$23.83M	$3.58B	$330.66M
7 Day Performance	75.71%	-3.56%	-2.12%	-1.35%
1 Month Performance	86.36%	6.31%	3.27%	-0.64%
1 Year Performance	-9.96%	48.30%	26.33%	19.08%

Agenus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGEN Agenus	2.7246 of 5 stars	$6.22 +1.6%	$30.00 +382.3%	-12.9%	$254.59M	$114.20M	3.85	440	Trending News Analyst Forecast Options Volume Analyst Revision Gap Up
MYGN Myriad Genetics	2.0668 of 5 stars	$6.03 +0.7%	$6.50 +7.8%	+9.7%	$565.74M	$824.50M	N/A	2,700
XOMA XOMA Royalty	3.2961 of 5 stars	$43.85 +2.0%	$53.75 +22.6%	+48.0%	$539.26M	$52.15M	27.93	10	News Coverage Positive News Gap Up
CBIO Crescent Biopharma	2.1596 of 5 stars	$16.96 -0.8%	$29.00 +71.0%	+21.1%	$470.95M	$10.84M	N/A	50	Positive News
EBS Emergent Biosolutions	2.1451 of 5 stars	$8.18 -1.2%	$12.00 +46.7%	+9.2%	$427.22M	$742.90M	N/A	2,420

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGEN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agenus (AGEN) Competitors

AGEN vs. MYGN, XOMA, CBIO, EBS, and VSTM

How does Agenus compare to Myriad Genetics?

Summary

How does Agenus compare to XOMA Royalty?

Summary

How does Agenus compare to Crescent Biopharma?

Summary

How does Agenus compare to Emergent Biosolutions?

Summary

How does Agenus compare to Verastem?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agenus (AGEN) Competitors

AGEN vs. MYGN, XOMA, CBIO, EBS, and VSTM

How does Agenus compare to Myriad Genetics?

Which has better valuation and earnings, AGEN or MYGN?

Do insiders & institutionals believe in AGEN or MYGN?

Is AGEN or MYGN more profitable?

Which has more risk & volatility, AGEN or MYGN?

Does the media refer more to AGEN or MYGN?

Do analysts prefer AGEN or MYGN?

Summary

How does Agenus compare to XOMA Royalty?

Which has more risk and volatility, XOMA or AGEN?

Which has stronger earnings & valuation, XOMA or AGEN?

Does the media favor XOMA or AGEN?

Is XOMA or AGEN more profitable?

Do insiders and institutionals believe in XOMA or AGEN?

Do analysts prefer XOMA or AGEN?

Summary

How does Agenus compare to Crescent Biopharma?

Do analysts rate AGEN or CBIO?

Which has preferable valuation & earnings, AGEN or CBIO?

Which has more volatility & risk, AGEN or CBIO?

Do insiders and institutionals have more ownership in AGEN or CBIO?

Does the media refer more to AGEN or CBIO?

Is AGEN or CBIO more profitable?

Summary

How does Agenus compare to Emergent Biosolutions?

Which has higher valuation & earnings, EBS or AGEN?

Do analysts rate EBS or AGEN?

Does the media prefer EBS or AGEN?

Which has more volatility and risk, EBS or AGEN?

Is EBS or AGEN more profitable?

Do insiders & institutionals have more ownership in EBS or AGEN?

Summary

How does Agenus compare to Verastem?

Is VSTM or AGEN more profitable?

Which has more risk & volatility, VSTM or AGEN?

Do institutionals and insiders have more ownership in VSTM or AGEN?

Do analysts rate VSTM or AGEN?

Which has stronger earnings and valuation, VSTM or AGEN?

Does the media favor VSTM or AGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools